Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab

20255 citationsJournal Article

Authors

Joseph J. Eron · University of North Carolina at Chapel Hill

Paul Cook · East Carolina University

Megha Mehrotra · Gilead Sciences (United States)

Hailin Huang · Gilead Sciences (United States)

Marina Caskey · Rockefeller University

Gordon E Crofoot · Clinical Research Organization

Linda Gorgos

Abstract

More inclusive bNAb susceptibility criteria may be appropriate for future studies of this combination treatment. Clinical Trials Registration. NCT04811040.

Topics & Keywords

HIV/AIDS drug development and treatment Chronic Lymphocytic Leukemia Research HIV Research and Treatment

Publication Details

Published in: The Journal of Infectious Diseases

Volume 231, Issue 6, pp. 1440-1444

DOI: 10.1093/infdis/jiaf159

Field-Weighted Citation Impact: 7.34

Command Palette

Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab

Authors

Abstract

Topics & Keywords

Publication Details